DK Life Science Co., Ltd. (KOSDAQ:303810)

Market Cap	118.02B -30.9%
Revenue (ttm)	130.34B -1.1%
Net Income	8.66B +285.7%
EPS	275.00 +243.8%
Shares Out	31.98M
PE Ratio	13.42
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,137,303
Average Volume	481,943
Open	3,430.00
Previous Close	3,400.00
Day's Range	3,390.00 - 4,045.00
52-Week Range	3,210.00 - 5,350.00
Beta	n/a
RSI	60.57
Earnings Date	n/a

About DK Life Science

DK Life Science Co., Ltd., a pharmaceutical company, develops and sells diagnostic medicines and medical devices in South Korea and internationally. It offers active pharmaceutical ingredients (API), injections, blood glucose self-monitoring device, Mobile CT equipment, and ultrasonic instruments. The company also offers catheters, MRI, CT scanner, ultrasound, mobile CT scanner, and X-ray equipment, as well as mammography image analysis assistance software. DK Life Science Co., Ltd. was founded in 2017 and is based in Seoul, South Korea.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2017
• Employees: 100
• Stock Exchange: KOSDAQ
• Ticker Symbol: 303810

Financial Performance

In 2025, DK Life Science's revenue was 130.34 billion, a decrease of -1.12% compared to the previous year's 131.82 billion. Earnings were 8.66 billion, an increase of 285.71%.